LYMPHOTOXIN BETA RECEPTOR AGENTS IN COMBINATION WITH CHEMOTHERAPEUTIC AGENTS

摘要

This invention features combination therapies that include a composition that activates lymphotoxin-beta receptor signaling in combination with one or more other chemotherapeutic agents, as well as therapeutic methods and screening methods for identifying agents that in combination with a lymphotoxin-beta receptor agonist agent have a supra-additive effect on tumor inhibition.